494 related articles for article (PubMed ID: 16541475)
1. Rituximab as therapy for refractory polymyositis and dermatomyositis.
Noss EH; Hausner-Sypek DL; Weinblatt ME
J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
[TBL] [Abstract][Full Text] [Related]
2. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case].
Yáñez V J; Cisternas M M; Saldías H V; Saldías P F
Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
Levine TD
Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
[TBL] [Abstract][Full Text] [Related]
4. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.
Qushmaq KA; Chalmers A; Esdaile JM
J Rheumatol; 2000 Dec; 27(12):2855-9. PubMed ID: 11128676
[TBL] [Abstract][Full Text] [Related]
6. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
Efthimiou P; Schwartzman S; Kagen LJ
Ann Rheum Dis; 2006 Sep; 65(9):1233-6. PubMed ID: 16476710
[TBL] [Abstract][Full Text] [Related]
7. [Dermatomyositis and polymyositis: clinical aspects and treatment].
Hachulla E
Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087
[TBL] [Abstract][Full Text] [Related]
8. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids.
Ramanan AV; Campbell-Webster N; Ota S; Parker S; Tran D; Tyrrell PN; Cameron B; Spiegel L; Schneider R; Laxer RM; Silverman ED; Feldman BM
Arthritis Rheum; 2005 Nov; 52(11):3570-8. PubMed ID: 16255046
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
11. Strength in polymyositis and dermatomyositis: best outcome in patients treated early.
Fafalak RG; Peterson MG; Kagen LJ
J Rheumatol; 1994 Apr; 21(4):643-8. PubMed ID: 8035387
[TBL] [Abstract][Full Text] [Related]
12. A pilot trial of rituximab in the treatment of patients with dermatomyositis.
Chung L; Genovese MC; Fiorentino DF
Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943
[TBL] [Abstract][Full Text] [Related]
13. Effect of early treatment in polymyositis and dermatomyositis.
Naji P; Shahram F; Nadji A; Davatchi F
Neurol India; 2010; 58(1):58-61. PubMed ID: 20228465
[TBL] [Abstract][Full Text] [Related]
14. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH
J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis.
Oddis CV; Medsger TA
J Rheumatol; 1988; 15(5):807-11. PubMed ID: 3172094
[TBL] [Abstract][Full Text] [Related]
17. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.
Fujisawa T; Suda T; Nakamura Y; Enomoto N; Ide K; Toyoshima M; Uchiyama H; Tamura R; Ida M; Yagi T; Yasuda K; Genma H; Hayakawa H; Chida K; Nakamura H
J Rheumatol; 2005 Jan; 32(1):58-64. PubMed ID: 15630726
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for refractory polymyositis: an open-label prospective study.
Mok CC; Ho LY; To CH
J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224
[TBL] [Abstract][Full Text] [Related]
19. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.
Hengstman GJ; van den Hoogen FH; van Engelen BG
Eur Neurol; 2004; 52(1):61-3. PubMed ID: 15240986
[No Abstract] [Full Text] [Related]
20. Inclusion body myositis: clinical and pathological boundaries.
Amato AA; Gronseth GS; Jackson CE; Wolfe GI; Katz JS; Bryan WW; Barohn RJ
Ann Neurol; 1996 Oct; 40(4):581-6. PubMed ID: 8871577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
